Related Experiment Video
Updated: Mar 18, 2026
High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities
Published on: November 15, 2013
[Not Available]
Marie-Dominique Tabone1, Nathalie Le Guyader2, Guy Leverger1
1Service d'Hémato-Oncologie Pédiatrique, Hôpital Trousseau, Paris, France.
Abstract:
Specificity of antifungals use in paediatric patients is linked to mycoses epidemiology in this population. Pharmacokinetics vary with patient age. Although studies are in progress, pharmacokinetic data in children are limited in number for most antifungals. Among antifungal agents, those approved in France for use in children are rare. Adverse event frequency can differ in children, as compared to frequency in adults, and drug interaction should be a major worry. Relative interest and cost of available forms in the paediatric population in not always taken into account. For each different situation, an optimal strategy of antifungals use in children should be determined.
Insights
Pediatric antifungal use requires careful consideration of mycoses epidemiology and age-related pharmacokinetics. Limited data and rare approvals necessitate tailored strategies for safe and effective antifungal treatment in children.
Area of Science:
- Pediatric pharmacology
- Mycology
- Infectious diseases
Context:
- Antifungal use in children is complex due to varying mycoses epidemiology.
- Pharmacokinetic data for most antifungals in pediatric populations are limited.
- Few antifungal agents are approved for pediatric use in France.
Purpose:
- To highlight the specific challenges of antifungal use in pediatric patients.
- To emphasize the need for age-specific pharmacokinetic data and approved medications.
- To underscore the importance of considering adverse events, drug interactions, and cost-effectiveness.
Summary:
- Antifungal efficacy and safety in children are influenced by age-specific pharmacokinetics and differing adverse event profiles compared to adults.
- Limited pharmacokinetic data and a scarcity of approved agents pose significant challenges in pediatric antifungal therapy.
- Optimal antifungal strategies must be individualized, considering epidemiology, pharmacokinetics, safety, and economic factors.
Impact:
- Informing the development of evidence-based guidelines for pediatric antifungal prescribing.
- Guiding further research into pediatric antifungal pharmacokinetics and clinical efficacy.
- Improving the safe and effective management of fungal infections in children.
